NCT00301028View on ClinicalTrials.gov

Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

Cetuximab

Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.

DRUG

Carboplatin

AUC 2 weekly for 6 courses.

DRUG

Paclitaxel

135 mg/m\^2 weekly for 6 courses.

PROCEDURE

Conventional Surgery

Following induction in second part of study.

RADIATION

Radiation Therapy

Following induction in second part of study.

Trial Locations (1)

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00301028 - Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter